Company news

Werewolf Therapeutics, Inc. news in 2025

Werewolf Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Werewolf Therapeutics Announces Pipeline and Business Updates

December 18, 2025

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

November 7, 2025

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

October 8, 2025

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

October 3, 2025

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

July 9, 2025

Werewolf Therapeutics to Participate in the BIO International Convention

June 12, 2025

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2025

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 20, 2025

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

May 13, 2025

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

May 5, 2025

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

April 17, 2025

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 11, 2025

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

March 4, 2025

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

February 24, 2025

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

January 12, 2025

Decks in 2025